BCIQ Profiles

Company Profile Report
0624 adu congress
BioCentury & Getty Images

Politics, Policy & Law

Bipartisan concern over cost of aducanumab could prompt CMS, Congress to act

CMS could limit access to Biogen’s Alzheimer’s drug or negotiate lower price

Jun 24, 2021 | 9:53 PM GMT

A day after Biogen and Eisai said in a statement that they are

Read the full 512 word article

How to gain access

Continue reading with a
two-week free trial.